Delhi-based integrated pharmaceuticals and research services firm Jubilant Organosys Limited through its subsidiary, Jubilant Biosys Limited, and Dr Naresh Trehan-controlled firm Medanta have announced their intention to develop a multi-faceted partnership with US-based Duke University to speed up the translation of discoveries by Duke scientists into clinical therapies.
Duke and Jubilant will work together over a period of five years to develop about five molecules and also plan to collaborate on two innovative “biomarker” studies to be conducted in Kolkata. “Jubilant will fund the pilot phase of these
studies in India,” said Shyam Bhartia, Chairman and Managing Director of Jubilant Organosys.
Jubilant and Duke will complete definitive agreements by the first quarter of 2010.
Medanta, in a joint venture with Duke Medicine will launch Medanta Duke Research Institute, a 60-bed clinical research facility.